New discovery about prostate cancer treatment

US scientists at the Karmanos Cancer Research Institute in Detroit in Michigan state have found that older men who choose hormone blockers to treat prostate cancer may be at risk. High incidence of cataracts.

The results of this study were published in the December issue of Annals of Epidemiology.

Image for illustrative purposes. (Internet source)

The male hormone testosterone can promote the development of prostate cancer. Therapy to prevent the production of Androgen (ADT) prevents testosterone production.

It is estimated that about one-third of men with prostate cancer use ADT therapy, either as either Lupron or Zoladex or as a testicular removal.

In her experiment, Dr. Jennifer Beebe-Dimmer and colleagues studied nearly 66,000 patients with prostate cancer aged 66 and older.

Of these, nearly half used ADT therapy within the first six months after being diagnosed, mostly under the use of hormonal drugs.

Results showed that about 111 new cases of cataract were diagnosed among 1,000 patients studied each year.

After taking into account other risk factors for cataract, scientists found that patients treated with hormone drugs were 9% more likely to develop cataracts. for those who do not use ADT therapy.

This risk increases to 26% for a smaller percentage of those who choose testicular removal.

Currently in the United States, there are about 20 million people aged 40 and older who have cataracts.